
Sign up to save your podcasts
Or


In this episode, we're joined by Dr. Dana DiRenzo to explore groundbreaking developments in the treatment of Sjögren's Disease. For the first time, therapies like BAFF blockade, CD40 ligand inhibitors, and FcRn antagonists appear poised to change the course of the disease—moving beyond symptom management to potential disease modification. We delve into the underlying science, current clinical trials, and tackle the big question: how early is early enough to begin treatment? Dr. DiRenzo also shares her expert perspective on holistic symptom management through what she calls the "4 Pillars of Health," offering practical strategies for improving quality of life for those living with Sjögren's.
By American College of Rheumatology4.9
6464 ratings
In this episode, we're joined by Dr. Dana DiRenzo to explore groundbreaking developments in the treatment of Sjögren's Disease. For the first time, therapies like BAFF blockade, CD40 ligand inhibitors, and FcRn antagonists appear poised to change the course of the disease—moving beyond symptom management to potential disease modification. We delve into the underlying science, current clinical trials, and tackle the big question: how early is early enough to begin treatment? Dr. DiRenzo also shares her expert perspective on holistic symptom management through what she calls the "4 Pillars of Health," offering practical strategies for improving quality of life for those living with Sjögren's.

504 Listeners

298 Listeners

128 Listeners

3,374 Listeners

1,150 Listeners

122 Listeners

120 Listeners

194 Listeners

141 Listeners

518 Listeners

367 Listeners

5 Listeners

183 Listeners

19 Listeners

6 Listeners